Molecular Insight Pharmaceuticals, Inc.
160 Second Street
Cambridge
Massachusetts
02142
United States
Tel: 617-492-5554
Fax: 617-492-5664
Email: jmccray@molecularinsight.com
About Molecular Insight Pharmaceuticals, Inc.
Molecular Insight is a privately held, emerging biopharmaceutical company based in Cambridge, Massachusetts. The company is focused on leveraging its proprietary technology platforms to develop innovative imaging pharmaceuticals that improve the visualization and management of disease. Molecular Insight has established a strong pipeline of product candidates focused on the large markets in cardiology, infectious disease, cancer and neurology. The company's lead compound, BMIPP for the detection of ischemia, is nearing completion of multi-center Phase II clinical trials.
The company's technology platforms are producing new radiopharmaceuticals that have the potential to detect the earliest changes in the molecular biology of the cell. Specific changes in gene expression, protein expression, protein function and biochemistry provide important insights into the nature and status of disease. These new technologies also promise to offer safer, more effective and less costly imaging procedures.
Molecular Insight's management team is led by David S. Barlow, Chairman and CEO. He has more than 20 years of management experience and achievements in the biopharmaceutical industry, most recently as President of Sepracor Pharmaceuticals. John W. Babich, Ph.D., President and CSO is a leader in the field of medical imaging and nuclear medicine and formerly on the faculty of Harvard Medical School and Massachusetts General Hospital. John E. McCray, Chief Operating Officer, has more than 20 years of operations, public policy experience in the biopharmaceutical industry. The company's scientific advisory board is chaired by William C. Eckelman, Ph.D., Chief of Positron Emission Tomography at the NIH Clinical Center.
Last Updated: 02-02-2007
153 articles about Molecular Insight Pharmaceuticals, Inc.
-
Progenics Pharmaceuticals, Inc. Acquires Molecular Insight Pharmaceuticals, Inc. to Expand Oncology-Focused Pipeline
1/22/2013
-
Molecular Insight Pharmaceuticals, Inc. Announces Initiation of Phase 2 Trial for Prostate Cancer Molecular Imaging Drug
9/25/2012
-
Molecular Insight Pharmaceuticals, Inc. Presents Clinical Oncology Data at Society of Nuclear Medicine 2012 Annual Meeting
6/14/2012
-
Molecular Insight Pharmaceuticals, Inc. Elects a New Board of Directors
2/23/2012
-
Molecular Insight Pharmaceuticals, Inc. Presents Human Data Demonstrating Detection of Metastatic Prostate Cancer
2/3/2012
-
Molecular Insight Pharmaceuticals, Inc. Release: Radiopharmaceutical for Targeted Treatment of Prostate Cancer to Enter Clinical Trials
1/30/2012
-
Molecular Insight Pharmaceuticals, Inc. Release: Radiopharmaceutical for Targeted Treatment of Prostate Cancer to Enter Clinical Trials
1/30/2012
-
Molecular Insight Pharmaceuticals, Inc. Presents Positive Phase 1 Prostate Cancer Data at the Annual Congress of the European Association of Nuclear Medicine
10/21/2011
-
Molecular Insight Pharmaceuticals, Inc.' Trofex Data Published in Journal of Nuclear Medicine
7/7/2011
-
Molecular Insight Pharmaceuticals, Inc. Presents Oncology Data at Society of Nuclear Medicine 2011 Annual Meeting
6/14/2011
-
Molecular Insight Pharmaceuticals, Inc. Announces Deregistration of Common Stock
5/16/2011
-
Molecular Insight Pharmaceuticals, Inc. Announces Confirmation of Plan of Reorganization
5/9/2011
-
Molecular Insight Pharmaceuticals, Inc. Announces Intention to Deregister Common Stock
5/4/2011
-
Molecular Insight Pharmaceuticals, Inc. Accepts Alternative Transaction Proposal and Files Amended Plan of Reorganization
3/9/2011
-
Molecular Insight Pharmaceuticals, Inc. Faces Uncertain Future in Chapter 11
1/31/2011
-
Molecular Insight Pharmaceuticals, Inc. Files for Chapter 11 After Bondholders Reject $45 Million Rescue Package from Savitr Capital LLC
12/10/2010
-
Johnson & Johnson's Molecular Insight Pharmaceuticals, Inc. Recalls Softchews Rolaids Antacids As Wood, Metal Found
12/10/2010
-
Molecular Insight Pharmaceuticals, Inc. Receives Extension of Waiver Agreement With Bond Holders
12/3/2010
-
Molecular Insight Pharmaceuticals, Inc. Receives Extension of Waiver Agreement With Bond Holders
11/22/2010
-
Molecular Insight Pharmaceuticals, Inc. Receives Extension of Waiver Agreement With Bond Holders
11/4/2010